EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Systemic therapies for atopic dermatitis

Rame Yousif, Dareen Elgindi, Amy S Paller

Journal of the American Academy of Dermatology · 2026

DOI: 10.1016/j.jaad.2026.01.075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Rame Yousif und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Amgen, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is a common, chronic, relapsing skin disorder characterized by eczematous lesions and intense pruritus, associated with reduced quality of life. Advanced systemic therapies (injectable biologics and oral Janus kinase inhibitors [JAKis]) for moderate-to-severe atopic dermatitis have transformed the options for patients. Dupilumab, a biologic targeting the interleukin-4 receptor, is now approved for patients as young as 6 months and improves comorbid allergic conditions, such as asthma and eosinophilic esophagitis. In the past 4 years, tralokinumab and lebrikizumab (both targeting interleukin-13) and the interleukin-31 receptor inhibitor, nemolizumab, have been approved for adolescents and adults. In contrast, oral JAKis, such as upadacitinib, abrocitinib, and baricitinib, inhibit the downstream JAK-signal transducers and activators of transcription pathway, providing rapid relief of pruritus and inflammation. Approved for adolescents and adults in the United States, JAKis expand therapeutic flexibility but carry greater safety considerations. This review highlights key systemic agents and discusses practical considerations in therapy selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsHumansAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalPyrazolesPurinesSulfonamidesPyrimidinesAzetidinesAdolescentAdultHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Janus Kinase inhibitoratopic dermatitisbiologicsdupilumabpediatric dermatology

Substanzen

Janus Kinase InhibitorsAntibodies, Monoclonal, HumanizeddupilumababrocitinibnemolizumabAntibodies, MonoclonalbaricitinibPyrazoleslebrikizumabPurines

Autor:innen und Institutionen

  • Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. Electronic address: apaller@n…

Förderung

  • Amgen
  • AbbVie

Zitieren

APA

Yousif, R., Elgindi, D., & Paller, A. S. (2026). Systemic therapies for atopic dermatitis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.01.075

Vancouver

Yousif R, Elgindi D, Paller AS. Systemic therapies for atopic dermatitis. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.01.075

BibTeX
@article{Yousif2026,
  author = {Yousif, Rame and Elgindi, Dareen and Paller, Amy S},
  title = {Systemic therapies for atopic dermatitis},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2026.01.075}
}
Kostenlos starten →